BR112021019334A2 - Anticorpos de cadeia pesada que se ligam ao psma - Google Patents

Anticorpos de cadeia pesada que se ligam ao psma

Info

Publication number
BR112021019334A2
BR112021019334A2 BR112021019334A BR112021019334A BR112021019334A2 BR 112021019334 A2 BR112021019334 A2 BR 112021019334A2 BR 112021019334 A BR112021019334 A BR 112021019334A BR 112021019334 A BR112021019334 A BR 112021019334A BR 112021019334 A2 BR112021019334 A2 BR 112021019334A2
Authority
BR
Brazil
Prior art keywords
psma
heavy chain
bind
antibodies
chain antibodies
Prior art date
Application number
BR112021019334A
Other languages
English (en)
Inventor
Ben Buelow
Kevin Dangv
Starlynn Clarke
Van Schooten Wim
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of BR112021019334A2 publication Critical patent/BR112021019334A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

anticorpos de cadeia pesada que se ligam ao psma. a presente invenção refere-se a anticorpos anti-psma de cadeia pesada (por exemplo, uniabstm), juntamente com métodos de produção de tais anticorpos, composições, incluindo composições farmacêuticas, compreendendo tais anticorpos, e seu uso para tratar distúrbios que são caracterizados pela expressão de psma.
BR112021019334A 2019-04-05 2020-04-03 Anticorpos de cadeia pesada que se ligam ao psma BR112021019334A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962830130P 2019-04-05 2019-04-05
PCT/US2020/026686 WO2020206330A1 (en) 2019-04-05 2020-04-03 Heavy chain antibodies binding to psma

Publications (1)

Publication Number Publication Date
BR112021019334A2 true BR112021019334A2 (pt) 2021-12-07

Family

ID=70476405

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019334A BR112021019334A2 (pt) 2019-04-05 2020-04-03 Anticorpos de cadeia pesada que se ligam ao psma

Country Status (17)

Country Link
US (2) US20220195068A1 (pt)
EP (1) EP3947470A1 (pt)
JP (1) JP2022526595A (pt)
KR (1) KR20210149076A (pt)
AU (1) AU2020252556A1 (pt)
BR (1) BR112021019334A2 (pt)
CA (1) CA3133654A1 (pt)
CL (1) CL2021002586A1 (pt)
CO (1) CO2021013279A2 (pt)
CR (1) CR20210500A (pt)
EA (1) EA202192736A1 (pt)
IL (1) IL286398A (pt)
JO (1) JOP20210253A1 (pt)
MX (1) MX2021012205A (pt)
PE (1) PE20220142A1 (pt)
SG (1) SG11202111027WA (pt)
WO (1) WO2020206330A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811490XA (en) 2016-06-21 2019-01-30 Teneobio Inc Cd3 binding antibodies
BR122022002481A8 (pt) 2016-09-14 2023-02-07 Teneobio Inc Anticorpos biespecíficos de ligação específica para cd3delta-epsilon
CA3065951A1 (en) 2017-06-20 2018-12-27 Teneoone, Inc. Anti-bcma heavy chain-only antibodies
WO2018237037A2 (en) 2017-06-20 2018-12-27 Teneobio, Inc. HEAVY CHAIN ANTIBODY ONLY ANTI-BCMA
CR20200322A (es) 2017-12-22 2021-01-12 Teneobio Inc Anticuerpos de cadena pesada que se unen a cd22
WO2020252366A1 (en) 2019-06-14 2020-12-17 Teneobio, Inc. Multispecific heavy chain antibodies binding to cd22 and cd3
CA3176792A1 (en) * 2020-04-29 2021-11-04 Katherine HARRIS Anti-cd3 and anti-bcma bispecific antibodies wth modified heavy chain constant regions
EP4284838A2 (en) * 2021-01-28 2023-12-06 Janssen Biotech, Inc. Psma binding proteins and uses thereof
KR20230148828A (ko) * 2021-02-25 2023-10-25 테네오바이오, 인코포레이티드 항-psma 항체 및 car-t 구조
CR20230525A (es) * 2021-04-16 2024-02-19 Teneobio Inc Anticuerpos anti-cd20 y estructuras car-t
JP2024517701A (ja) 2021-04-29 2024-04-23 アムジエン・インコーポレーテツド 組換え生産タンパク質の低分子量種を低減させる方法
WO2023183231A1 (en) 2022-03-21 2023-09-28 Amgen Inc. Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP1578447A4 (en) 2002-10-31 2009-06-03 Genentech Inc METHODS AND COMPOSITIONS THAT CAN INCREASE ANTIBODY PRODUCTION
AU2004205684A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
PL1776383T3 (pl) 2004-07-22 2015-02-27 Univ Erasmus Med Ct Rotterdam Cząsteczki wiążące
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
IL293719B2 (en) * 2015-05-21 2023-07-01 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
CN108473589B (zh) * 2016-01-12 2023-05-02 克雷森多生物制剂有限公司 结合前列腺特异性膜抗原(psma)的分子
SG11201811490XA (en) 2016-06-21 2019-01-30 Teneobio Inc Cd3 binding antibodies
BR122022002481A8 (pt) 2016-09-14 2023-02-07 Teneobio Inc Anticorpos biespecíficos de ligação específica para cd3delta-epsilon
GB201711068D0 (en) * 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA

Also Published As

Publication number Publication date
KR20210149076A (ko) 2021-12-08
JP2022526595A (ja) 2022-05-25
WO2020206330A1 (en) 2020-10-08
US20220195068A1 (en) 2022-06-23
EP3947470A1 (en) 2022-02-09
SG11202111027WA (en) 2021-11-29
PE20220142A1 (es) 2022-01-27
CR20210500A (es) 2021-11-05
CL2021002586A1 (es) 2022-05-06
IL286398A (en) 2021-10-31
EA202192736A1 (ru) 2022-01-27
MX2021012205A (es) 2022-02-21
CA3133654A1 (en) 2020-10-08
JOP20210253A1 (ar) 2023-01-30
CO2021013279A2 (es) 2022-01-17
CN113710707A (zh) 2021-11-26
AU2020252556A1 (en) 2021-10-21
US20230242668A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
CO2021008696A2 (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112017013661A8 (pt) Conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica
CY1123231T1 (el) Ενωσεις τετραϋδροπυριμιδοδιαζεπινης και τετραϋδροπυριδοδιαζεπινης για θεραπεια πονου και καταστασεων σχετικων με τον πονο
CO2020006453A2 (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
BR112022011824A2 (pt) Anticorpos de cadeia pesada que se ligam a cd38
MX2020009130A (es) Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos.
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
CL2021003215A1 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y métodos de uso de estos
BR112022027101A2 (pt) Anticorpos multiespecíficos que se ligam a bcma
CO2023013500A2 (es) Anticuerpos anti-cd19 y estructuras car-t
CL2023003073A1 (es) Anticuerpos anti-cd20 y estructuras car-t
BR112022002761A2 (pt) Proteínas de ligação a 4-1bb e ox40 e composições e métodos relacionados, anticorpos contra 4-1bb, anticorpos contra ox40
UY36922A (es) Inhibidores de asgr
EA201992886A1 (ru) Активируемые антитела против pdl1 и способы их применения
BR112022004809A2 (pt) Compostos 2-amino-s6-tiopurina substituídos como inibidores da proteína enpp1
EA202092981A1 (ru) Антитела к l1cam и их применение